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Background: Direct interaction between Red blood cells (RBCs) and platelets is known for a long time. The
bleeding time is prolonged in anemic patients independent of their platelet count and could be corrected by
transfusion of RBCs, which indicates that RBCs play an important role in hemostasis and platelet activation.
However, in the last few years, opposing mechanisms of platelet inhibition by RBCs derived nitric oxide (NO) were
proposed. The aim of our study was to identify whether RBCs could produce NO and activate soluble guanylate
cyclase (sGC) in platelets.
Methods: To test whether RBCs could activate sGC under different conditions (whole blood, under hypoxia, or
even loaded with NO), we used our well-established and highly sensitive models of NO-dependent sGC activation
in platelets and activation of purified sGC. The activation of sGC was monitored by detecting the phosphorylation
of Vasodilator Stimulated Phosphoprotein (VASPS239) by flow cytometry and Western blot. ANOVA followed by
Bonferroni’s test and Student’s t-test were used as appropriate.
Results: We show that in the whole blood, RBCs prevent NO-mediated inhibition of ADP and TRAP6-induced
platelet activation. Likewise, coincubation of RBCs with platelets results in strong inhibition of NO-induced sGC
activation. Under hypoxic conditions, incubation of RBCs with NO donor leads to Hb-NO formation which inhibits
sGC activation in platelets. Similarly, RBCs inhibit activation of purified sGC, even under conditions optimal for
RBC-mediated generation of NO from nitrite.
Conclusions: All our experiments demonstrate that RBCs act as strong NO scavengers and prevent NO-mediated
inhibition of activated platelets. In all tested conditions, RBCs were not able to activate platelet or purified sGC.
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The main role of RBCs in the human body is to trans-
port O2 from lungs to different tissues and CO2 back to
lungs. Recently studies propose that RBCs, under certain
conditions, can produce NO and inhibit platelet activa-
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mechanisms responsible for platelet inhibition. However,
the activation of platelet sGC/cGMP/PKG by NO released
from RBCs was not directly proven.
Therefore, the main aim of our work was to test
whether RBCs can release NO that can stimulate platelet
sGC. Incubating RBCs with purified sGC and platelets
under normal and hypoxic conditions, did not induce
sGC activation indicating that NO is not released from
RBCs under tested conditions. Rather, externally added
NO onto whole blood was scavenged by RBCs, thereby
preventing sGC activation in platelets. Our data strongly
indicate that RBCs do not release biologically active NOle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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highly sensitive NO receptor.Background
Red blood cells (RBCs) and platelets represent the major
cell population in mammalian blood. Functional interac-
tions between RBCs and platelets are known for a long
time from clinical observations. The bleeding time is
prolonged in patients with anemia independent on their
platelet count and could be corrected by RBCs transfu-
sion, and bleeding defects are directly connected with
platelet function but not with the blood coagulation
system [1–3]. On the other hand, RBCs transfusion
could increase platelet activation and might be danger-
ous in treatment of coronary artery diseases [4]. These
clinical observations clearly pointed out that RBCs, by
still unidentified mechanism(s), play some important
role in platelet activation. However, recently in several
papers [5–9] platelet inhibition by RBCs-derived NO
was described. In all these papers, platelet inhibition by
deoxygenated RBCs, that can reduce nitrite to NO was
shown. Importantly, in none of these papers direct
activation of platelet soluble Guanylate Cyclase (sGC) by
RBCs-derived NO was shown. In papers where the
inhibition of platelet function by nitrite/RBCs was
described [5–9], platelet activation was assessed by aggre-
gometry and flow cytometry, which is not sufficient to
confirm whether the inhibition was due to the activation
of NO/cGMP pathway in platelets. Several publications
described direct NO production from RBCs by endo-
thelial NO synthase (eNOS) [10, 11], but other studies
did not find any functionally active NOS in RBCs [12].
The direct activation of platelet sGC by RBCs was
never shown before. Hence, the connection between
RBCs, eNOS and hemoglobin (Hb) to platelet sGC acti-
vation and platelet inhibition cannot be proven.
Hb and RBCs are involved in the modulation of NO
signaling and metabolism. Since the discovery of NO as
a signaling molecule, numerous studies proposed the
formation of the nitrosyl-heme adduct of Hb (NO-Hb),
a source of bioavailable NO. The nitrosylation of
conserved cysteine of Hb β-chain (β93Cysteine) by NO
and the formation of S-Nitrosohemoglobin (SNO-Hb)
were proposed as putative mechanisms for Hb functioning
as NO carrier [13, 14]. These interactions between NO
and Hb are superseded by the fast reaction between NO
and oxyhemoglobin (oxyHb). According to mathematical
modelling and experimental data, most of NO in the blood
is annihilated by the fast irreversible reaction of oxyHb
with NO, which yields oxidized Hb (methemoglobin,
metHb) and nitrate [15]. On the other hand, deoxyhemo-
globin (deoxy-Hb) may act as a nitrite reductase, promot-
ing the synthesis of NO from inorganic nitrite [16, 17].The high affinity NO receptor, sGC mediates most of
the biological functions of NO, especially at low NO
concentrations [18, 19]. Although different reactions be-
tween NO and Hb were established, the mechanisms of
NO/SNO release from Hb are not well understood. It is
less clear how NO can be released from RBCs under
physiologic conditions of overwhelming excess of free
Hb. It remains to be proved that RBCs-derived NO can
activate platelet sGC.
Endogenous NO is a well-known and potent inhibitor
of platelet activation (reviewed in [20, 21]). NO-
dependent inhibition of platelets is solely mediated by
sGC [22]. Intact platelet sGC is highly sensitive to en-
dogenous NO and even nanomolar NO concentrations
are sufficient for cGMP generation [23]. In platelets,
Protein Kinase G (PKG), which phosphorylates multiple
substrates responsible for platelet inhibition, is the major
downstream target of cGMP [21]. For evaluation of plate-
let sGC activity, we developed a highly sensitive method,
based on NO/sGC/cGMP/PKG dependent phosphoryl-
ation of vasodilator-stimulated phosphoprotein (VASP) in
human platelets, which has been used in numerous stud-
ies [20]. Most studies that report NO release from RBCs
had been performed using blood vessel relaxation experi-
ments or with isolated washed RBCs. However, both
approaches were not sufficient to answer the question
whether RBCs can produce biologically active NO/SNO.
Vasorelaxation is a complex process controlled not only
by NO, but also by a number of other vasodilators.
Moreover, the experiments with isolated RBCs never
demonstrated that NO or other reactive nitrogen species
generated by RBCs result in activation of sGC.
In this report, we directly addressed this question by
determining the sGC-dependent signaling in intact
platelets and the activation of purified sGC. Our data
clearly showed that RBCs, under the tested conditions,
cannot activate platelet sGC or purified sGC, but in
contrast, they act as a potent NO scavengers.Methods
Materials
DEA-NO (Biomol, Hamburg, Germany), iloprost (Ilome-
din; Schering, Berlin, Germany), Thrombin Receptor
Activating Peptide-6 (TRAP-6) (Bachem, Weil am Rhein,
Germany) were purchased. Antibody against actin, L-
arginine, L-NG-Nitroarginine methyl ester (L-NAME),
NG-Methyl-L-arginine (L-NMA), and phenylephrine
were obtained from Sigma (Munich, Germany). The
PAC-1-FITC and CD-41-FITC antibodies were obtained
from BD-Bioscience (Heidelberg, Germany). Antibodies
against VASP (Ser239) were from Nano Tools (Teningen,
Germany). sGC and PKG I antibodies were described
previously [24, 25].
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and RBCs
Human platelets were prepared as reported previously
[26]. Blood was collected from healthy volunteers,
and WBCs were isolated by Leucosep tubes (Greiner,
Frickenhausen, Germany) according to the manufac-
turer’s instructions. WBC concentration was adjusted
to 6×106/ml. RBCs were collected after separation of
PRP and washed thrice with HEPES buffer; the super-
natant from the last wash was used as control to
confirm the absence of free Hb. For experiments with
RBCs, suspensions which did not contain free
hemoglobin were used.
Platelet aggregation
Aggregation in whole blood was measured by Multiplate
(Roche Diagnostics, Mannheim, Germany), in PRP and
washed platelets by Apact4004 (LabiTec, Ahrensburg,
Germany) aggregometers. Citrated whole blood was pre-
incubated with sodium nitroprusside (SNP) and aggrega-
tion was initiated by ADP (10 μM). PRP and washed
platelets were preincubated for 1 min with SNP or ilo-
prost and aggregation was initiated by ADP.
FACS analysis
FACS analysis was performed using a Becton Dickinson
FACS Calibur with CELL Quest software, version 3.1f
(Becton Dickinson, Heidelberg, Germany). Platelets in
the whole blood were identified by CD41 staining.
Washed platelets concentration was adjusted to 3×108/ml
and for washed platelets/RBC mixture 4.5×109/ml washed
RBCs were added to platelet suspension. All samples after
stimulation were directly fixed with 3 % formaldehyde.
The samples were incubated with PAC-1-FITC, or
CD41-FITC antibodies and analysed by FACS. For
phospho-VASP, the samples were permeabilized with
0.2 % Triton X-100.Western blot analysis
Samples were lysed with Laemmli buffer and the proteins
were separated by SDS-PAGE and transferred to nitro-
cellulose membrane as described [27]. Membranes were
incubated with primary antibodies overnight at 4 °C. Goat
anti-rabbit or anti-mouse IgG conjugated with horseradish
peroxidase were used as secondary antibodies followed by
ECL detection. Blots were analysed densitometrically
using NIH Image J software for uncalibrated optical
density.
Experiments with deoxygenated washed platelets and
RBCs
HEPES buffer was degassed under vacuum and bub-
bled with argon. This buffer was used for washingand resuspension of washed platelets and RBCs.
RBCs and platelets were further bubbled with argon
and kept under argon in closed gas-tight tubes.
Then, RBCs were washed 3 times with argon-
saturated HEPES to wash out free hemoglobin from
lysed RBCs. In some experiments deoxy-RBCs were
incubated with DEA-NO and/or with NaNO2 prior
addition to platelet suspension. For experiments
with purified sGC, preparations of deoxy-RBC were
also transferred into an anaerobic glove chamber
(Model 110 V, Coy Laboratory Products, Inc.)
and equilibrated for additional 2 h in anaerobic
environment.
Spectral analysis of Hb
To confirm the Hb status of RBCs, UV spectra were
taken for oxy-Hb, and deoxy-Hb after incubation with
NO donor. 10 μl of RBC were lysed in hypoosmotic
media (HEPES buffer diluted by water to 50 mOsm),
and the visible absorption spectra in the 450–700 nm
range were immediately collected on a UV–vis Spectro-
photometer (SPECS SSP-715, Spectroscopy Systems,
Russia).
sGC activity assay
Full-length human sGC was expressed in insect Sf9
cells as described previously [28]. Recombinant sGC
was purified using anion exchange and Ni-affinity
chromatography as detailed previously [29]. Anaerobic
sGC was prepared in an anaerobic train as described
previously, [19] and transferred into the anaerobic
glove chamber. Enzymatic sGC activity was assayed
using a modified [α-32P]GTP to [32P]cGMP conver-
sion assay [30] with buffers prepared anaerobically
and equilibrated in the anaerobic chamber overnight.
To measure NO-induced activity, 0.01 μg sGC in
10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM DTT,
3 mM MgCl2, was incubated with indicated RBCs or
buffer prior to exposure to the mixture containing
NO donor (DEA-NO) and GTP. To determine if
RBCs generate any bioavailable NO from nitrite, an-
aerobic RBCs were incubated at 37°C for 15 s or
5 min with indicated amount of nitrite, prior to the
addition to 0.1 μg sGC. The cGMP-forming reaction
was initiated by 1 mM GTP/[α-32P]GTP (~100,000 cpm).
The reaction was stopped by zinc carbonate precipitation
and processed following the protocol established previ-
ously [30].
Data analysis
All experiments were performed at least thrice, and data
are expressed as means ± SEM. Differences between
groups were analyzed by ANOVA followed by Bonferroni’s
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Fig. 1 NO-dependent platelet inhibition is blunted in the presence
of RBCs. a ADP-induced platelet aggregation measured in the
whole blood, platelet rich plasma (PRP) and washed platelets
(WP). Aggregation in whole blood was measured by Multiplate,
in PRP and WP by Apact 4004 aggregometer. For whole blood,
300 μl of citrated whole blood and 300 μl saline were added to
the test cell together with indicated concentrations of SNP. After
three minutes of incubation at 37 °C, aggregation was initiated
by ADP (10 μM). Aggregation curves were recorded for 6 min.
PRP and WP samples were preincubated for 1 min with indicated
concentrations of SNP or iloprost and aggregation was initiated by
10 μm of ADP and monitored for 3 min. Data of platelet aggregation
are presented as area under the curve (AUC). b FACS analysis of
integrin αIIbβ3 activation (Pac-1 binding) measured in the whole
blood, PRP, washed platelets (WP), and WP with washed RBCs
(109/ml). Samples were prepared as described under “Materials
and Methods”. Data are presented as mean ± SEM, n = 4; +p < 0.05,
compared to control, *p < 0.05 compared to Whole blood sample
preincubated with DEA-NO
Gambaryan et al. Cell Communication and Signaling  (2016) 14:16 Page 4 of 12test and Student’s t-test as appropriate. p < 0.05 was con-
sidered statistically significant.
Results
RBCs prevent NO donor-mediated platelet response
Inhibition of platelet aggregation by RBCs-generated NO
was reported in several publications [5, 7, 11, 31]. To
test whether RBCs influence platelet aggregation, we
measured ADP-triggered aggregation in whole blood,
PRP, and washed platelets. In whole blood, very high
(50 and 100 μM) concentrations of Sodium nitroprus-
side (SNP) were required for partial inhibition of platelet
aggregation (25 ± 4 and 32 ± 6 %, respectively). On the
contrary, in PRP and washed platelets, 0.5 μM SNP was
sufficient to achieve similar degrees of inhibition. Activa-
tion of cAMP/Protein Kinase A (PKA) signaling by
iloprost (5 nM) completely inhibited platelet aggregation
in all the three preparations (Fig. 1a). Corroborating the
aggregation studies, NO donor (DEA-NO) significantly
inhibited TRAP-6 induced integrin (αIIbβ3) activation in
PRP and washed platelets, but not in whole blood or in
washed platelets coincubated with washed RBCs. Ilo-
prost, used as a positive control in these experiments,
completely prevented integrin αIIbβ3 activation (Fig. 1b).
To prove that the platelet inhibitory response was
mediated by PKG and PKA activation, we measured
VASP phosphorylation on the same sets of experiments.
DEA-NO only slightly (1.7 ± 0.3 fold) increased VASP
phosphorylation in the whole blood samples, whereas in
PRP and washed platelets the increase of VASP phos-
phorylation was more than 25-fold and comparable with
the iloprost-induced response. Coincubation of washed
platelets with washed RBCs completely prevented DEA-
NO-induced VASP phosphorylation (Fig. 2a). It was
recently [31] reported that in RBCs, activation of eNOS
by L-arginine has an inhibitory effect on platelet aggre-
gation. However, this study did not determine whether
the inhibition is due to the activation of sGC/cGMP/
PKG pathway in platelets. To address this issue, we
incubated the whole blood with L-arginine or NOS
inhibitor (L-NAME) and measured platelet VASP phos-
phorylation by FACS analysis. Neither inhibition, nor
stimulation of NOS in whole blood affected VASP phos-
phorylation (Fig. 2b).
Presence of RBCs prevents NO-induced PKG activation in
platelets
In the next series of experiments, we examined whether
longer incubation of RBCs with platelets activates plate-
let PKG. We also assessed the RBC concentration neces-
sary to inhibit NO-dependent activation of PKG. Since
VASP phosphorylation by PKG is the primary parameter
evaluated in this set of studies, we first tested by West-
ern blotting whether the key elements of the NO/cGMPpathway downstream of eNOS are detectable in RBCs.
The lysate from 108/ml platelets exhibited a strong sig-
nal for sGC, PKG and VASP. In contrast, these proteins
were not detected in RBCs (109/ml) (Fig. 3a).
Next, we observed that incubation of RBCs with
platelets in suspension for up to 30 min does not
increase the phosphorylation of VASP. Corroborating
aggregation experiments, the strong phosphorylation of
VASP induced by DEA-NO was completely abolished by
RBC (Fig. 3b). The titration of RBCs demonstrated that
even 108 RBCs/ml, which is ~50-fold lower than the
physiological RBC count, were sufficient to prevent NO-
induced phosphorylation of VASP in platelets (Fig. 3c).
Neither inhibition, nor stimulation of NOS in RBCs
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Fig. 2 Inhibition of platelet PKG activation in the presence of RBCs.
a FACS analysis of VASP phosphorylation at S239 measured in the
whole blood, PRP, washed platelets, and WP with washed RBCs
(109/ml). b VASP phosphorylation at S239 measured in the whole
blood in the presence of L-arginine or NOS inhibitor L-NAME
(both 200 μM, 10 min preincubation). NO donor (DEA-NO, 5 μM,
2 min) was used as positive control. Samples were prepared as
described under “Materials and Methods”. Data are presented as
mean ± SEM, n = 4; +p < 0.05, compared to control
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in line with the results from whole blood (Fig. 2b).
sGC is a very sensitive receptor for NO, which evolved
to respond to nanomolar concentrations of NO [32].
While oxyhemoglobin is a very efficient NO scavenger,
the affinity of oxygen-free hemoglobin for NO is com-
parable to sGC. It was previously shown that deoxygen-
ated RBCs can produce S-nitroso-L-cystein (L-SCNO)
and S-nitrosoglutathione (GSNO) [33]. Therefore, we
tested whether deoxygenated RBCs affect NO-dependent
activation of purified sGC and platelet sGC/PKG path-
way. Exogenously added L-CSNO and GSNO are strong
activators of purified and platelet sGC (data not shown).
However, presence of deoxygenated RBCs had no effecton purified sGC activity and only inhibited DEA-NO-
induced sGC activation (Fig. 3e). Similar results were
observed, if RBCs were incubated with DEA-NO prior
to the addition to sGC (data not shown).
Because of the high NO scavenging properties of free
Hb [34], special care was taken to assure that the RBC
suspensions did not contain free Hb as a result of haem-
olysis. In all our experiments, we used supernatant from
RBCs as a control for the absence of free Hb. In contrast
to the addition of RBCs, supernatant from RBCs added
to the platelet suspension had no effect on DEA-NO-
induced VASP phosphorylation. Also, RBCs and super-
natant of RBCs had no influence on PKA-induced VASP
phosphorylation stimulated by iloprost (Fig. 4a). Platelet
cGMP levels are affected not only by the elevation of
cGMP through sGC activation, but also by the inhibition
of cGMP-degrading phosphodiesterases. Phosphodiester-
ase 5 (PDE5) is the main PDE responsible for cGMP deg-
radation in platelets [21]. Therefore, we tested whether
RBCs may cause inhibition of PDE5 in platelets. The
PDE5 inhibitor sildenafil induced similar VASP phosphor-
ylation in platelet suspension with and without added
RBCs (Fig. 4b) indicating that platelet PDE5 was not af-
fected by RBCs.
Neither deoxygenation, nor addition of nitrate promote
RBC-induced sGC activation
The nitrate-nitrite-NO reductive pathway is an alternative
source for NO, which plays a significant role in bacteria
and plants [35]. In mammals, the oxygen-independent ni-
trite reductive pathway was implicated in hypoxic vaso-
dilation [36–38] and control of blood pressure. Some
studies showed that RBCs promote nitrite/NO-dependent
vasodilation and inhibition of platelet aggregation under
hypoxic conditions [7, 39, 40]. We recently showed that
incubation of platelets with carbonic anhydrase purified
from bovine RBCs in the presence of nitrite increases
platelet cGMP content and induces VASP phosphorylation
[41]. Therefore, it was important to test whether intact
RBCs containing Hb in different status (oxyHb, deoxyHb,
NO-Hb), with or without nitrite, and normal or deoxygen-
ated platelets, can activate platelet sGC. Incubation of
platelets with different concentrations of nitrite had no ef-
fect on PKG-dependent phosphorylation of VASP (Fig. 5a).
These results on human platelets are consistent with a
report on mouse platelets that nitrite triggers VASP phos-
phorylation only in the presence of PDE5 inhibitor [42].
Next, we co-incubated deoxygenated RBCs loaded with
NO (deoxy RBC +DEA-NO) with deoxygenated platelets
in the presence of increasing nitrite concentrations.
Even under these conditions, we found no activation of
platelet PKG (Fig. 5b). We tested all possible combina-
tions of RBCs containing Hb in different status (oxyHb,
deoxyHb, NO-Hb), with or without nitrite, and normal
- 109 108 107 106 105 0  0      RBCs/ml
- + +       +      +      +       +    +      DEA-NO



































































































































































Fig. 3 Inhibition of sGC activity by RBCs. a Western blot analysis of sGC, PKG, VASP, and actin expression in platelet and RBC lysates. Upper panel
represent Western blot and lower panel represent Ponceau-S-stained membrane. b-d) Western blot analysis of VASPS239 phosphorylation
in platelets (3x108/ml) treated with 1 μM DEA-NO in the presence of RBCs (5x108/ml, in 10 μl). b Platelets were coincubated with RBCs
(109/ml, 10 μl), or the same volume (10 μl) of supernatant from the last wash of RBCs for indicated time. When indicated, samples were
treated with DEA-NO (1 μM, 30 min). c Indicated amount of RBCs (10 μl) were added to platelet suspension for 10 min, and then stimulated with DEA-
NO (1 μM, 1 min). When indicated, the same volume (10 μl) of supernatant from the last wash of RBCs was added to the platelets. For the bar graphs,
immunoblots were scanned and quantified by the Image J program. The intensity of the VASPSer239 signal was normalized to the total VASP signal,
which was designated as 1 in control samples. Results are means ± SEM, n = 4, + significant difference from control samples. d Platelets (3x108/ml)
were coincubated with RBC (5x108/ml, 10 μl) and treated with L-Arginine, L-NAME, or L-NMA for 10 min. When indicated, samples were treated with
DEA-NO (10 μM, 1 min). Total VASP blots served as loading control. Shown are representative blots of three independent experiments. e Basal and
NO-induced (1 μM DEA-NO) purified sGC activity measured in anaerobic conditions after incubation with buffer or indicated amounts of RBC. Data are
presented as mean ± SEM, n = 4
Gambaryan et al. Cell Communication and Signaling  (2016) 14:16 Page 6 of 12or deoxygenated platelets, and found no evidence of
activated platelet PKG (Fig. 5a, b, and other data not
shown). To confirm that intact RBCs in the presence of
nitrite do not produce NO, we incubated deoxygenated
RBCs with nitrite and measured the activity of purifiedsGC. Anaerobic RBCs preincubated with 100 μM nitrite
did not elevate purified sGC activity (Fig. 5c), which is
consistent with strong NO-scavenging effect of RBCs.
The same results were observed when the experiments
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Fig. 4 RBCs inhibits platelet PKG stimulated by NO donors, but not by
PDE5 inhibition. a, b Western blot analysis of VASPS239 phosphorylation
in platelets (3x108/ml) stimulated by DEA-NO (1 μM, 1 min), iloprost
(2 nm, 1 min) or sildenafil (1 μM, 5 min) in the presence of washed
RBCs (1x 108, 10 μl) or supernatant (10 μl) from last wash of RBCs.
a Supernatant from RBC (10 μl) washed by HEPES buffer, or RBCs
(1x108/ml, 10 μl) were added to platelets for 10 min, then stimulated
with DEA-NO, or iloprost. b RBCs (108/ml, 10 μl), or supernatant from
RBC (10 μl) were added to platelets for 10 min, then stimulated with
DEA-NO, or with sildenafil. Total VASP blots served as loading control.
Shown are representative blots of 4 independent experiments. For the
bar graphs, immunoblots were scanned and quantified by the Image J
program. The intensity of the VASPSer239 signal was normalized to the
total VASP signal, which was designated as 1 in control samples. Re-
sults are means ± SEM, n = 4, + significant difference from
control samples
Gambaryan et al. Cell Communication and Signaling  (2016) 14:16 Page 7 of 1210 μM nitrite (data not shown). To confirm the Hb
status of RBCs, UV spectra were taken from each
sample (Fig. 5d). Each spectrum corresponds to well-
characterised Hb pattern of oxyHb (RBC), deoxyHb(RBC + Argon), NO-Hb (RBC + Argon + DEA-NO) and
visible amount of metHb after 30 min incubation with
DEA-NO [43].
Endothelial cell-derived NO is the main source of platelet
sGC activation
In blood vessels, endothelial cells or circulating lympho-
cytes express NOS isoforms and may potentially be the
source of NO for activation of platelet sGC/cGMP/PKG
pathway. To evaluate the contribution of endothelial
cells and lymphocytes, we co-incubated washed platelets
with washed WBCs, or human umbilical vein endothelial
cells (HUVECs) in the presence of L-arginine or L-
NAME. Incubation of platelets with WBCs in the pres-
ence of L-arginine did not activate platelet PKG, however,
NOS activity of WBCs was slightly increased by L-
arginine and inhibited by L-NAME. It is likely that the
amount of NO produced by WBCs in our experimental
setting was not sufficient for activation of platelet sGC. In
contrast, NO producted by HUVECs, which can be inhib-
ited by L-NAME, strongly stimulates platelet sGC (Fig. 6)
suggesting that endothelial cell-derived NO is the main
source of platelet sGC activation. Our in vitro data are in
good agreement with in vivo mouse models, where it was
shown that eNOS of endothelial cells exerts a direct anti-
thrombotic effects on platelets [44].
Discussion
The key role of RBCs in hypoxic vasodilation is well
known. RBCs trigger sGC activation in the smooth
muscle cells of the vessel wall that leads to vessel dila-
tion. Few publications report that RBCs release NO dur-
ing hypoxia, thus activating sGC. Several mechanisms
were proposed to argue the NO carrying properties of
RBCs/Hb. In one mechanism, Hb nitrosyl-heme adduct
(NO-Hb) is regarded as a form of NO storage and car-
rier. NO released from NO-Hb under hypoxic condi-
tions results in vasodilation [36]. According to another
proposed mechanism, S-nitrosylated Cys93 of the Hb β-
chain is an equally important source of NO/SNO [45].
However, later studies on mice with mutated β93Cys
demonstrated that Cys93-Hb is not important for RBC-
induced vasodilation [13, 14]. Finally, NO reduced from
nitrite by deoxyhemoglobin was considered as an ex-
planation for hypoxic vasodilation [39, 40, 46]. However,
this hypothesis was strongly criticized by others [15].
Strong NO scavenging properties of oxyhemoglobin in
hypoxic condition is considered to be an important
requirement for effective nitrite/RBCs-dependent NO
generation or release. However, the link between RBCs
and sGC activation is clearly missing because direct
activation of sGC by NO or SNO released from RBCs is
not experimentally shown. Nevertheless, until now, NO












































































Fig. 5 Deoxygenated RBCs loaded with NO did not stimulate platelet PKG. a Western blot analysis of VASPS239 phosphorylation in platelets
(3x108/ml) stimulated by DEA-NO (1 μM, 1 min), or incubated (10 min) with indicated concentrations of NaNO2. Experiment was done under
argon. b Washed platelets and RBCs were deoxygenated by argon. RBCs (1x 108/ml) were washed 3 times by deoxygenated HEPES buffer,
deoxygenated for additional 30 min and then incubated with DEA-NO (50 μM, 30 min) and added (1x108/ml in 10 μl) to platelets together with
indicated concentrations of NaNO2 for 10 min. 10 μl of supernatant from the last wash was used as control for free Hb. Total VASP served as
loading control. Shown are representative blots of four independent experiments. c sGC activity was measured under anaerobic conditions after
incubation with 100 μM sodium nitrite and indicated amount of RBCs, as described in Method section. Data are presented as mean ± SEM, n = 4.
d UV-visible spectra of oxyHb, deoxyHb, and deoxyHb loaded with NO. Hb spectra were taken from, oxygenated, deoxygenated (under argon), or
deoxy-RBCs incubated for 15 and 30 min with 50 μM DEA-NO. Shown are representative spectra from four independent experiments
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platelet inhibition. As RBCs-induced vasodilation might
be controlled by other NO-independent mechanisms, we
focused our study on the effects of RBC on platelet and
purified sGC.
The main aim of our study was to establish whether
RBCs could promote sGC activation by releasing NO/SNO under any possible conditions (in whole blood,
under hypoxia, or even loaded with NO). To answer the
question whether RBCs can activate sGC, we used our
well-established model of NO-dependent sGC/cGMP/
PKG activation in platelets and NO-mediated activation
of purified sGC. Both these systems are highly sensitive

















































































Fig. 6 Endothelial cell-derived NO is the only source of platelet PKG activation. Western blot analysis of VASPS239 phosphorylation in platelets
(3x108/ml). Washed platelets were coincubated with WBCs (7x106/ml) for 10 min, or added to the confluent HUVECs cultured in 24 well plate for
10 min then L-arginine or L-NAME (200 μM each, 10 min) were added to the samples. After 10 min, incubation, WBCs were separated from
platelets by centrifugation and suspensions of non-adhered platelets were collected from HUVECs for Western blot analysis. As a control washed
platelets and WBCs (7x106/ml) alone were stimulated with DEA-NO (1 μM, 1 min). In addition, WBCs were incubated with the same concentration/time
with L-Arginine and L-NAME. Shown are representative blots of four independent experiments. Total VASP served as loading control. For the bar
graphs, immunoblots were scanned and quantified by the Image J program. The intensity of the VASPSer239 signal was normalized to the total VASP
signal, which was designated as 1 in control samples. Results are means ± SEM, n = 4, + significant difference from control samples
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mations indicate a high number of molecules of sGC
(3700), PKG (3500) and VASP (44000) per single platelet
[47]. This high concentration of NO receptor and down-
stream signaling molecules makes platelets a very sensi-
tive model for detection of NO-dependent sGC
activation. PKA and PKG phosphorylate VASP at serines
157 and 239, respectively. In platelets, PKA and PKG
can equally phosphorylate both sites. We argue that if
RBCs-released NO/SNO is sufficient to induce vasodila-
tion, platelet sGC must be activated in the RBCs/platelet
suspension. Only one paper [7] showed more than 3
times increase of platelet cGMP concentration after
5 min incubation with 0.1 μM nitrate, and addition of
RBCs further increases cGMP more than 5 times. In this
paper, cGMP was measured by the enzyme-linked im-
munoassay from Cayman Chemicals. It is important to
mention that such a high cGMP increase (comparable
with NO donors effect) should undoubtedly activate
platelet PKG, which was not shown in this manuscript.
We specifically addressed this question and used several
cGMP determination assays from different suppliers,
however we were not able to reproduce their results.
Apparently, nitrite itself, and especially RBCs, interfere
with cGMP assays and, in some cases, might give
erroneous increase of platelet cGMP. After summarizing
results of eight experiments from different assays, wedid not detect any statistically significant cGMP accrual
in platelets incubated with nitrite and RBCs. It should
be mentioned that direct measurement of cGMP levels
in platelets, is complex and prone to artefacts, therefore
we did not include these data. This question has been
described in details in our recent review [48]. VASP
phosphorylation at Ser239 mediated by PKG, which is
even more sensitive than determination of cGMP itself
[49] is now accepted as one of the most commonly used
standards for evaluation of sGC/cGMP/PKG system ac-
tivation, especially in platelets. Therefore, in all our ex-
periments we used VASP Ser239 phosphorylation as a
readout of PKG activation mediated by cGMP increase.
We also tested whether RBCs activate purified sGC,
which is sensitive to low NO/SNO concentrations [29].
The experiments presented in the current report clearly
demonstrated that RBCs did not directly stimulate
purified sGC, under normoxic or hypoxic conditions or
in the presence of nitrite. Moreover, RBCs at physio-
logical concentration, completely inhibited sGC activa-
tion even by micromolar concentrations of NO donor
(Fig. 3b-e). Washed RBCs do not express detectable
amount of sGC, PKG, and VASP (Fig. 3a). Therefore, in
the experiments with RBCs/platelet suspension, the
phospho-VASP signal reflects the activation of sGC in
platelets. These experiments also show lack of platelet
sGC activation in the presence of RBCs and nitrite.
Gambaryan et al. Cell Communication and Signaling  (2016) 14:16 Page 10 of 12We should emphasize that thorough washing of RBCs
is required because of the strong NO-scavenging by free
Hb released from lysed RBCs. In about 1/3 of our
experiments (these data were excluded) the supernatant
of RBCs, which was always used as a control for free Hb
contamination, inhibited NO-mediated VASP phosphor-
ylation. It should be noted that in all papers describing
inhibition of platelet activation by RBCs [5–7, 50], the
results were assessed by aggregometry. In such experi-
mental setting, RBCs-induced effects other than NO/
cGMP-mediated platelet inhibition cannot be ruled out.
The experiments performed with whole blood (Fig. 2b)
or with RBC/platelet suspension (Fig. 3d) demonstrated
that stimulation/inhibition of NOS had no effect on
platelet sGC activation. Our studies demonstrated that
L-arginine-stimulated NO synthesis in WBCs is suffi-
cient for sGC activation in WBCs, but not of platelet
sGC (Fig. 6). However, these data do not exclude that
under other experimental conditions WBC-produced
NO could activate platelet sGC as well.
RBCs and platelets are the major cell populations in
blood, however until now little is known about interac-
tions between these two cell types. RBCs are involved in
thrombus formation, but it is not clear which functional
role they play in the development of thrombosis [51].
There are no indications in the literature concerning
direct platelet/RBCs interactions. In vivo, circulating
platelets are continuously exposed to activating and inhi-
biting factors. RBCs are one of the sources of platelet ac-
tivating factors like ATP, ADP and Hb released from
injured RBCs, which scavenges NO. Hemolysis of RBCs
which leads to increase of free Hb, ADP and ATP in
plasma is the main reason of platelet hyperreactivity in
sickle cell disease patients [52, 53]. On the other hand,
endothelial cells derived NO and prostacyclin are the
major platelet inhibitory factors. A well-regulated equi-
librium between these two opposing processes is import-
ant for the normal hemostasis and an impairment of this
equilibrium will promote thrombotic or bleeding disor-
ders. Our experiments support the clinical data [1–3]
that RBCs play only stimulatory role in platelets and
they are not involved in platelet inhibitory pathways.
Conclusions
All our data demonstrated that RBCs act as strong NO
scavengers and prevent NO-mediated inhibition of
platelet. In all tested conditions, RBCs were not able to
activate platelet or purified sGC.
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